{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036408","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-08-06T21:22:52+00:00","discovered_at":"2026-08-06T21:24:32.729598+00:00","generated_at":"2026-08-06T21:24:47.814971+00:00","sec_items":["1.01","5.08","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AIM ImmunoTech enters $1.5M manufacturing agreement with Sterling Pharma for Ampligen drug substance","bullets":["Agreement with Sterling Pharma Solutions to manufacture PolyI and Poly C12U (precursors to Ampligen) at Dudley, UK site.","Estimated cost ~$1.5M over 12 months; includes process development, non-GMP demo batches, analytical method validation, and one cGMP batch each.","Product intended for ongoing and future clinical trials, including potential Phase 3 for metastatic pancreatic cancer.","Shareholder director nominations for 2026 annual meeting must be received between Aug 18 and Sep 17, 2026; universal proxy deadline Oct 19, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036408","json":"https://secwatch.observer/filing/0001493152-26-036408.json","markdown":"https://secwatch.observer/filing/0001493152-26-036408.md","text":"https://secwatch.observer/filing/0001493152-26-036408.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226036408/0001493152-26-036408-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226036408/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T21:24:47.814971+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}